DNA 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 용도별, 지역별, 부문별 예측(2025-2030년)

DNA Diagnostics Market Growth & Trends:

The global DNA diagnostics market size is expected to reach a value of USD 14.14 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is due to advancements in genome sequencing and the development of personalized DNA-level diagnostic applications. In addition, the rising number of government-sponsored patented research initiatives and funded projects are anticipated to further drive demand in the market. For instance, in December 2022, the UK government announced a funding of USD 229.4 (£175) million for the development and creation of advanced genomic research.

The market growth is highly driven by the introduction of novel technologies for genome profiling. Moreover, with the increasing incidence of chronic oncology and infectious diseases that rely on DNA prototyping for treatment and diagnosis through personalized medicine, the demand for DNA diagnostics/testing-based research is anticipated to increase significantly over the forecast period. Furthermore, the increasing demand for DNA diagnostics/testing is driven by the rising demand for prenatal testing, and in-vitro fertilization is expected to provide positive growth prospects to the market. In September 2022, Eurofins Genoma announced the launch of niPGT-A, an embryo-free, non-invasive preimplantation screening test.

DNA diagnostics enables the comprehensive analysis of tumor genomes through techniques such as next-generation sequencing (NGS). NGS allows for the simultaneous sequencing of multiple genes, providing a detailed view of the genetic alterations present in the tumor. By comparing the tumor genome with normal tissue DNA, scientists and clinicians can identify specific mutations, copy number variations, and structural rearrangements unique to the cancer cells. In June 2022, Illumina, a DNA sequencing and array-based technology provider, introduces a research test developed in collaboration with Merck, aimed at unlocking deeper insights into the tumor genome.

Hepatitis C virus (HCV) is a global health concern, affecting millions of people worldwide. Accurate and timely diagnosis of HCV is crucial for effective treatment and prevention of further transmission. In this context, DNA diagnostics has emerged as a powerful tool for detecting and managing HCV infections. In July 2022, Roche introduced a groundbreaking dual antigen and antibody diagnostic test Elecsys HCV Duo, to aid the global efforts in eradicating the hepatitis C virus.

DNA Diagnostics Market Report Highlights:

• The PCR-based diagnostics segment held the largest share of 49.40% in 2024, the dominance of this segment can be attributed to the widespread market usage and the increase in product availability due to the rising number of key players introducing innovative PCR-based diagnostics
• NGS DNA diagnosis is projected to grow fastest CAGR of 13.9% over the forecast period owing to advancements in high-throughput sequencing technologies that enable comprehensive genetic analyses.
• Cancer genetics tests segment held the largest share of 29.80% in 2024. DNA sequencing technologies are increasingly utilized to identify and characterize various cancer types and genetic disorders.
• North America DNA diagnostics market dominated the overall global market and accounted for the 42.72% revenue share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Application
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Application outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. DNA Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. DNA Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. DNA Diagnostics Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. DNA Diagnostics Market: Technology Movement Analysis
• 4.3. DNA Diagnostics Market by Technology Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. PCR-based Diagnostics
  • 4.5.1. PCR-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. NGS DNA Diagnosis
  • 4.6.1. NGS DNA Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. In-Situ Hybridization Diagnostics
  • 4.7.1. In-Situ Hybridization Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Microarrays-based Diagnostics
  • 4.8.1. Microarrays-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Other Technologies
  • 4.9.1. In Other Technologies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. DNA Diagnostics Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. DNA Diagnostics Market: Application Movement Analysis
• 5.3. DNA Diagnostics Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Cancer Genetics Tests
  • 5.5.1. Cancer Genetics Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Infectious Diseases DNA Testing
  • 5.6.1. Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. HBV Diagnostic
    • 5.6.2.1. HBV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. TB Diagnostic
    • 5.6.3.1. TB Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. CT/NG Diagnostic
    • 5.6.4.1. CT/NG Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. HPV Diagnostic
    • 5.6.5.1. HPV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. MRSA Diagnostic
    • 5.6.6.1. MRSA Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Others
    • 5.6.7.1. Others Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Newborn Genetic Screening
  • 5.7.1. Newborn Genetic Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Preimplantation & Reproductive Diagnosis
  • 5.8.1. Preimplantation & Reproductive Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Non-Infectious Diseases DNA Testing
  • 5.9.1. Non-Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.2. Cardiovascular Diseases
    • 5.9.2.1. Cardiovascular Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.3. CNS & PNS Related
    • 5.9.3.1. CNS & PNS Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.4. Skeletal, Connective, Ectodermal & Dermal DNA Testing
    • 5.9.4.1. Skeletal, Connective, Ectodermal & Dermal DNA Testing Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.5. Lung, Kidney, Liver & GT Related
    • 5.9.5.1. Lung, Kidney, Liver & GT Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9.6. Sensory Diseases
    • 5.9.6.1. Sensory Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Prenatal DNA Carrier Screening
  • 5.10.1. Prenatal DNA Carrier Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Pharmacogenomics/Drug Metabolism
  • 5.11.1. Pharmacogenomics/Drug Metabolism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.12. Hematology & Immunology/Identity Diagnostics & Forensics
  • 5.12.1. Hematology & Immunology/Identity Diagnostics & Forensics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.13. Others
  • 5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. DNA Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional DNA Diagnostics Market movement analysis
• 6.3. DNA Diagnostics Market: Regional Estimates & Trend Analysis by Technology, Biomaterial & End-use
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. U.S. DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2.2. Key Country Dynamics
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Scenario
    • 6.5.2.5. Competitive Scenario
  • 6.5.3. Canada
    • 6.5.3.1. Canada DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3.2. Key Country Dynamics
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Scenario
    • 6.5.3.5. Competitive Scenario
  • 6.5.4. Europe
  • 6.5.5. Europe DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. UK
    • 6.5.6.1. UK DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6.2. Key Country Dynamics
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Scenario
    • 6.5.6.5. Competitive Scenario
  • 6.5.7. Germany
    • 6.5.7.1. Germany DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7.2. Key Country Dynamics
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Scenario
    • 6.5.7.5. Competitive Scenario
  • 6.5.8. France
    • 6.5.8.1. France DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8.2. Key Country Dynamics
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Scenario
    • 6.5.8.5. Competitive Scenario
  • 6.5.9. Italy
    • 6.5.9.1. Italy DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9.2. Key Country Dynamics
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Scenario
    • 6.5.9.5. Competitive Scenario
  • 6.5.10. Spain
    • 6.5.10.1. Spain DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.10.2. Key Country Dynamics
    • 6.5.10.3. Regulatory Framework
    • 6.5.10.4. Reimbursement Scenario
    • 6.5.10.5. Competitive Scenario
  • 6.5.11. Denmark
    • 6.5.11.1. Denmark DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.11.2. Key Country Dynamics
    • 6.5.11.3. Regulatory Framework
    • 6.5.11.4. Reimbursement Scenario
    • 6.5.11.5. Competitive Scenario
  • 6.5.12. Norway
    • 6.5.12.1. Norway DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.12.2. Key Country Dynamics
    • 6.5.12.3. Regulatory Framework
    • 6.5.12.4. Reimbursement Scenario
    • 6.5.12.5. Competitive Scenario
  • 6.5.13. Sweden
    • 6.5.13.1. Sweden DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.13.2. Key Country Dynamics
    • 6.5.13.3. Regulatory Framework
    • 6.5.13.4. Reimbursement Scenario
    • 6.5.13.5. Competitive Scenario
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Japan DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2.2. Key Country Dynamics
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Scenario
    • 6.6.2.5. Competitive Scenario
  • 6.6.3. China
    • 6.6.3.1. China DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3.2. Key Country Dynamics
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Scenario
    • 6.6.3.5. Competitive Scenario
  • 6.6.4. India
    • 6.6.4.1. India DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4.2. Key Country Dynamics
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Scenario
    • 6.6.4.5. Competitive Scenario
  • 6.6.5. South Korea
    • 6.6.5.1. South Korea DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5.2. Key Country Dynamics
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Scenario
    • 6.6.5.5. Competitive Scenario
  • 6.6.6. Australia
    • 6.6.6.1. Australia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6.2. Key Country Dynamics
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Scenario
    • 6.6.6.5. Competitive Scenario
  • 6.6.7. Thailand
    • 6.6.7.1. Thailand DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7.2. Key Country Dynamics
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Scenario
    • 6.6.7.5. Competitive Scenario
• 6.7. Latin America
  • 6.7.1. Latin America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2.1. Brazil DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2.2. Key Country Dynamics
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Scenario
    • 6.7.2.5. Competitive Scenario
  • 6.7.3. Argentina
    • 6.7.3.1. Argentina DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3.2. Key Country Dynamics
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Scenario
    • 6.7.3.5. Competitive Scenario
  • 6.7.4. Mexico
    • 6.7.4.1. Mexico DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4.2. Key Country Dynamics
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement Scenario
    • 6.7.4.5. Competitive Scenario
• 6.8. Middle East & Africa
  • 6.8.1. Middle East & Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. South Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2.2. Key Country Dynamics
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Scenario
    • 6.8.2.5. Competitive Scenario
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Saudi Arabia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3.2. Key Country Dynamics
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Scenario
    • 6.8.3.5. Competitive Scenario
  • 6.8.4. UAE
    • 6.8.4.1. UAE DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4.2. Key Country Dynamics
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Scenario
    • 6.8.4.5. Competitive Scenario
  • 6.8.5. Kuwait
    • 6.8.5.1. Kuwait DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5.2. Key Country Dynamics
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Scenario
    • 6.8.5.5. Competitive Scenario

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Company Categorization
• 7.3. Strategy Mapping
  • 7.3.1. NEW PRODUCT LAUNCH
  • 7.3.2. PARTNERSHIPS
  • 7.3.3. ACQUISITION
  • 7.3.4. COLLABORATION
• 7.4. Key Company Market Share Analysis, 2024
• 7.5. Key Company Profiles
  • 7.5.1. Abbott
    • 7.5.1.1. Company overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Technology benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. F. Hoffmann-La Roche Ltd.
    • 7.5.2.1. Company overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Technology benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. QIAGEN
    • 7.5.3.1. Company overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Technology benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. Bio-Rad Laboratories, Inc.
    • 7.5.4.1. Company overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Technology benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Thermo Fisher Scientific, Inc.
    • 7.5.5.1. Company overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Technology benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. Illumina, Inc.
    • 7.5.6.1. Company overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Technology benchmarking
    • 7.5.6.4. Strategic initiatives
  • 7.5.7. Hologic, Inc.
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Technology benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Agilent Technologies Inc.
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Technology benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Siemens Healthineers AG
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Technology benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Danaher Corporation
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Technology benchmarking
    • 7.5.10.4. Strategic initiatives